Phase 4 N=399 Colchicine Or Naproxen Treatment for ACute gouT
Gout
Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=402 Celebrex In Acute Gouty Arthritis Study
Arthritis, Gouty
Primary: Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity — 3.03; 2.73; 2.84; 2.83 Scores on a scale
Phase 2 N=82 A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Gout Flares
Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356
Phase 3 N=185 MPC-004 for the Treatment of an Acute Gout Flare
Gout
Primary: Responders — 17; 28; 9 Participants
Phase 4 N=74 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Gout
Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34
Phase 4 N=35 Does Allopurinol Prolong a Treated, Acute Gout Flare?
Gout
Primary: Resolution of the Acute Gout Attack — 15.4; 13.4 days — p=0.5
Phase 2 N=6 Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
Arthritis, Gouty
Primary: Percentage of Participants With Improvement in Gout at 72 Hours Post-dose Using a Likert Scale — 100; 100 Percentage of participants
Phase 2 N=127 A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
Gout
Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants
Phase 3 N=225 Study Utilizing Rilonacept in Gout Exacerbations
Acute Gout Flare
Primary: Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours — -1.40; -1.55; -0.69…
Phase 2 N=165 A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis
Acute Gouty Arthritis
Primary: Change in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS — -26.1…
Phase 2 N=200 Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
Acute Gout
Primary: The Dose of Canakinumab for Treatment of Acute Flares in Gout Patients That Leads to the Same Efficacy as Triamcinolone Acetonide With Respect to Pain Intensity on a…
Phase 2 N=314 Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
Joint Damage
Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472
Phase 3 N=230 Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
Acute Gout
Primary: Time to First New Flare — NA; NA Days
Phase 3 N=226 Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
Acute Gout
Primary: Time to First New Flare: Survival Analysis During the 12 Weeks of Study — NA; NA Days
N/A N=1,463 Virtual Gout Clinic
Gout
Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants
N/A N=60 Gout Self-Monitoring Aiming to Reach Target
Gout
Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants
Phase 3 N=397 Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
Acute Gouty Arthritis
Primary: Number of Participants Who Reported Adverse Events — 78; 65; 64 Participants
Phase 3 N=397 Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
Acute Gouty Arthritis
Primary: Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups — 17.1; 32 Millimeters
N/A N=43 The Diet Gout Trial
Gout · Hyperuricemia
Primary: Uric Acid Level — 8.23; 8.03 mg/dL
Phase 2 N=143 A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
Gout · Hyperuricemia
Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants
Phase 2 N=341 Long Term Study of Canakinumab (ACZ885) in Patients With Gout
Gouty Arthritis
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 31; 52; 9; 15 Participants
Phase 3 N=248 PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16) — 1.23; 0.35; 0.34 Gout flares
Phase 4 N=940 CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
Gout · Chronic Kidney Diseases
Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001
Phase 2 N=432 A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
Gout
Primary: Core Study: Mean Number of Gout Flares Per Participant — 0.5; 0.4; 0.2; 0.4 Gout flares
Phase 2 N=20 Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Gout
Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale
Phase 3 N=1,315 Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
Gout
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 59.1; 66.6; 13.0; 27.5 percentage of participants
Phase 2 N=37 Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
Gout
Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants
Phase 4 N=82 Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol
Intercritical Gout
Primary: Number of Gout Flares Per Participant From Day 1 to Week 16 — 1.1; 0.3 gout flares
Phase 2 N=152 Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
Gout Chronic · Hyperuricemia
Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…
Phase 3 N=241 PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
Intercritical Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16) — 1.06; 0.29; 0.21 Number of Gout flares per participant